Hebei Wan Sui Pharma Co., Ltd. romanized
Check drug filings and source records for this company-name string.
Listed by the company name as recorded in the source, without merging affiliated entities.
Page reference 97d52fcde8
These counts cover loaded acceptance records only. First-applicant and co-applicant counts are not added together. CDE data as of 2026/11/13 06:42.
Drug filings
33 acceptance records as first applicant, grouped into 27 source drug names. Source data as of 2026/11/13 06:42.
Acceptance records are de-duplicated by acceptance number. Drug names are normalized only for width and whitespace; dosage forms and combinations remain separate. Application types are retained from the source. Expand a drug to inspect each record. Published drugs link to their drug pages; other names do not create new public drug pages.
复方板蓝根颗粒 · No verified English name 1 records · Latest accepted 2026/11/02
Supplement · 1
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYZB2605417 | Supplement | 2026/11/02 | Hebei Wan Sui Pharma Co., Ltd. romanized | CDE ↗ |
板蓝根颗粒 · No verified English name 2 records · Latest accepted 2026/11/02
Supplement · 2
白带丸 · No verified English name 1 records · Latest accepted 2026/11/02
Supplement · 1
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYZB2605437 | Supplement | 2026/11/02 | Hebei Wan Sui Pharma Co., Ltd. romanized | CDE ↗ |
肾石通颗粒 · No verified English name 1 records · Latest accepted 2026/11/02
Supplement · 1
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYZB2605419 | Supplement | 2026/11/02 | Hebei Wan Sui Pharma Co., Ltd. romanized | CDE ↗ |
通脉颗粒 · No verified English name 1 records · Latest accepted 2026/11/02
Supplement · 1
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYZB2605418 | Supplement | 2026/11/02 | Hebei Wan Sui Pharma Co., Ltd. romanized | CDE ↗ |
龙胆泻肝丸 · No verified English name 1 records · Latest accepted 2026/11/02
Supplement · 1
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYZB2605436 | Supplement | 2026/11/02 | Hebei Wan Sui Pharma Co., Ltd. romanized | CDE ↗ |
Valsartan and Amlodipine Tablets(I) 2 records · Latest accepted 2026/09/02
Supplement · 1Generic · 1
Dapagliflozin Tablets 2 records · Latest accepted 2026/07/23
Generic · 2
开胸顺气丸 · No verified English name 1 records · Latest accepted 2026/04/09
Supplement · 1
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYZB2601333 | Supplement | 2026/04/09 | Hebei Wan Sui Pharma Co., Ltd. romanized | CDE ↗ |
强筋健骨丸 · No verified English name 1 records · Latest accepted 2026/04/09
Supplement · 1
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYZB2601345 | Supplement | 2026/04/09 | Hebei Wan Sui Pharma Co., Ltd. romanized | CDE ↗ |
当归拈痛丸 · No verified English name 1 records · Latest accepted 2026/04/09
Supplement · 1
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYZB2601342 | Supplement | 2026/04/09 | Hebei Wan Sui Pharma Co., Ltd. romanized | CDE ↗ |
接骨丸 · No verified English name 1 records · Latest accepted 2026/04/09
Supplement · 1
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYZB2601334 | Supplement | 2026/04/09 | Hebei Wan Sui Pharma Co., Ltd. romanized | CDE ↗ |
气管炎丸 · No verified English name 1 records · Latest accepted 2026/04/09
Supplement · 1
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYZB2601346 | Supplement | 2026/04/09 | Hebei Wan Sui Pharma Co., Ltd. romanized | CDE ↗ |
活血解痛膏 · No verified English name 1 records · Latest accepted 2026/04/09
Supplement · 1
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYZB2601338 | Supplement | 2026/04/09 | Hebei Wan Sui Pharma Co., Ltd. romanized | CDE ↗ |
清热解毒颗粒 · No verified English name 2 records · Latest accepted 2026/04/09
Supplement · 2
风热咳嗽丸 · No verified English name 1 records · Latest accepted 2026/04/09
Supplement · 1
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYZB2601341 | Supplement | 2026/04/09 | Hebei Wan Sui Pharma Co., Ltd. romanized | CDE ↗ |
风痛安胶囊 · No verified English name 1 records · Latest accepted 2026/04/09
Supplement · 1
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYZB2601340 | Supplement | 2026/04/09 | Hebei Wan Sui Pharma Co., Ltd. romanized | CDE ↗ |
骨刺丸 · No verified English name 1 records · Latest accepted 2026/04/09
Supplement · 1
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYZB2601356 | Supplement | 2026/04/09 | Hebei Wan Sui Pharma Co., Ltd. romanized | CDE ↗ |
山花晶 · No verified English name 1 records · Latest accepted 2026/04/03
Supplement · 1
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYZB2601273 | Supplement | 2026/04/03 | Hebei Wan Sui Pharma Co., Ltd. romanized | CDE ↗ |
麝香狗皮膏 · No verified English name 1 records · Latest accepted 2026/04/03
Supplement · 1
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYZB2601272 | Supplement | 2026/04/03 | Hebei Wan Sui Pharma Co., Ltd. romanized | CDE ↗ |
威灵骨刺膏 · No verified English name 1 records · Latest accepted 2026/03/07
Supplement · 1
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYZB2600792 | Supplement | 2026/03/07 | Hebei Wan Sui Pharma Co., Ltd. romanized | CDE ↗ |
枇杷清肺颗粒 · No verified English name 1 records · Latest accepted 2024/11/28
New drug · 1
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CXZS2400036 | New drug | 2024/11/28 | Hebei Wan Sui Pharma Co., Ltd. romanized | CDE ↗ |
Febuxostat Tablets 2 records · Latest accepted 2024/09/15
Generic · 2
Dapoxetine Hydrochloride Tablets 2 records · Latest accepted 2024/06/06
Generic · 2
Oseltamivir Phosphate Capsules 1 records · Latest accepted 2023/03/24
Generic · 1
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYHS2300896 | Generic | 2023/03/24 | Hebei Wan Sui Pharma Co., Ltd. romanized | CDE ↗ |
Tofacitinib Citrate Tablets 1 records · Latest accepted 2023/03/04
Generic · 1
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYHS2300687 | Generic | 2023/03/04 | Hebei Wan Sui Pharma Co., Ltd. romanized | CDE ↗ |
Vildagliptin Tablets 1 records · Latest accepted 2021/12/14
Generic · 1
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYHS2102185 | Generic | 2021/12/14 | Hebei Wan Sui Pharma Co., Ltd. romanized | CDE ↗ |
Changes in the last 90 days
7 events from 2026/08/16 to 2026/11/13. CDE data as of 2026/11/13 06:42; NMPA data as of 2026/11/12 18:32.
This source was last successfully updated at 2026/11/12 18:32; current coverage may be incomplete.
Last 90 days, ordered by fact date. Marketing approvals, trial registrations, supplements, notices and review changes are labelled separately. Fact dates are approval dates, acceptance dates, trial first-publication dates or complete-snapshot observation dates, as applicable. Publication and site-observation dates are separate. Historical backfills are not current-period new events. Exit records cover currently inactive applications with an identifiable complete snapshot, not a full review history.
Accepted: 7 applications
- 2026/11/02Accepted
白带丸 · No verified English name
CYZB2605437
Fact date: 2026/11/02 · Site observation date: 2026/11/03
View source ↗ - 2026/11/02Accepted
龙胆泻肝丸 · No verified English name
CYZB2605436
Fact date: 2026/11/02 · Site observation date: 2026/11/03
View source ↗ - 2026/11/02Accepted
肾石通颗粒 · No verified English name
CYZB2605419
Fact date: 2026/11/02 · Site observation date: 2026/11/03
View source ↗ - 2026/11/02Accepted
通脉颗粒 · No verified English name
CYZB2605418
Fact date: 2026/11/02 · Site observation date: 2026/11/03
View source ↗ - 2026/11/02Accepted
复方板蓝根颗粒 · No verified English name
CYZB2605417
Fact date: 2026/11/02 · Site observation date: 2026/11/03
View source ↗ - 2026/11/02Accepted
板蓝根颗粒 · No verified English name
CYZB2605416
Fact date: 2026/11/02 · Site observation date: 2026/11/03
View source ↗ - 2026/09/02Accepted
Valsartan and Amlodipine Tablets(I)
CYHB2601676
Fact date: 2026/09/02 · Site observation date: 2026/10/22
View source ↗
Under review
9 acceptance numbers with this company as first applicant are currently listed as under review by CDE. Source data as of 2026/11/13 06:42.
| Drug | Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|---|
| 白带丸 · No verified English name | CYZB2605437 | Supplement | 2026/11/02 | Hebei Wan Sui Pharma Co., Ltd. romanized | CDE ↗ |
| 龙胆泻肝丸 · No verified English name | CYZB2605436 | Supplement | 2026/11/02 | Hebei Wan Sui Pharma Co., Ltd. romanized | CDE ↗ |
| 肾石通颗粒 · No verified English name | CYZB2605419 | Supplement | 2026/11/02 | Hebei Wan Sui Pharma Co., Ltd. romanized | CDE ↗ |
| 通脉颗粒 · No verified English name | CYZB2605418 | Supplement | 2026/11/02 | Hebei Wan Sui Pharma Co., Ltd. romanized | CDE ↗ |
| 复方板蓝根颗粒 · No verified English name | CYZB2605417 | Supplement | 2026/11/02 | Hebei Wan Sui Pharma Co., Ltd. romanized | CDE ↗ |
| 板蓝根颗粒 · No verified English name | CYZB2605416 | Supplement | 2026/11/02 | Hebei Wan Sui Pharma Co., Ltd. romanized | CDE ↗ |
| Valsartan and Amlodipine Tablets(I) | CYHB2601676 | Supplement | 2026/09/02 | Hebei Wan Sui Pharma Co., Ltd. romanized | CDE ↗ |
| Dapagliflozin Tablets | CYHS2601768 | Generic | 2026/07/23 | Hebei Wan Sui Pharma Co., Ltd. romanized | CDE ↗ |
| Dapagliflozin Tablets | CYHS2601767 | Generic | 2026/07/23 | Hebei Wan Sui Pharma Co., Ltd. romanized | CDE ↗ |
Catalogue holder records
9 loaded active catalogue records whose holder name matches this source company name. Source data as of 2026/11/13 06:39. Manufacturer-only records are excluded.
| Drug | Marketing authorization holder | Manufacturer | Approval number | Approved | Catalogue category (source text) | View source |
|---|---|---|---|---|---|---|
| Febuxostat Tablets | Hebei Wan Sui Pharma Co., Ltd. romanized | Hebei Wan Sui Pharma Co., Ltd. romanized | 国药准字H20256399 | 2025/12/22 | Generic approved under the new chemical-drug registration classification | CDE ↗ |
| Febuxostat Tablets | Hebei Wan Sui Pharma Co., Ltd. romanized | Hebei Wan Sui Pharma Co., Ltd. romanized | 国药准字H20256400 | 2025/12/22 | Generic approved under the new chemical-drug registration classification | CDE ↗ |
| Dapoxetine Hydrochloride Tablets | Hebei Wan Sui Pharma Co., Ltd. romanized | Hebei Wan Sui Pharma Co., Ltd. romanized | 国药准字H20256188 | 2025/12/09 | Generic approved under the new chemical-drug registration classification | CDE ↗ |
| Dapoxetine Hydrochloride Tablets | Hebei Wan Sui Pharma Co., Ltd. romanized | Hebei Wan Sui Pharma Co., Ltd. romanized | 国药准字H20256187 | 2025/12/09 | Generic approved under the new chemical-drug registration classification | CDE ↗ |
| Valsartan and Amlodipine Tablets(I) | Hebei Wan Sui Pharma Co., Ltd. romanized | Hebei Wan Sui Pharma Co., Ltd. romanized | 国药准字H20253793 | 2025/04/01 | Generic approved under the new chemical-drug registration classification | CDE ↗ |
| Tofacitinib Citrate Tablets | Hebei Wan Sui Pharma Co., Ltd. romanized | Hebei Wan Sui Pharma Co., Ltd. romanized | 国药准字H20244998 | 2024/09/26 | Generic approved under the new chemical-drug registration classification | CDE ↗ |
| Oseltamivir Phosphate Capsules | Hebei Wan Sui Pharma Co., Ltd. romanized | Hebei Wan Sui Pharma Co., Ltd. romanized | 国药准字H20244303 | 2024/06/28 | Generic approved under the new chemical-drug registration classification | CDE ↗ |
| Vildagliptin Tablets | Hebei Wan Sui Pharma Co., Ltd. romanized | Hebei Wan Sui Pharma Co., Ltd. romanized | 国药准字H20233660 | 2023/06/07 | Generic approved under the new chemical-drug registration classification | CDE ↗ |
| Leflunomide Tablets | Hebei Wan Sui Pharma Co., Ltd. romanized | Hebei Wan Sui Pharma Co., Ltd. romanized | 国药准字H20080054 | 2021/12/07 | Drug that passed quality-and-efficacy consistency evaluation | CDE ↗ |
Only active catalogue records matching the source holder name are listed. A manufacturer role does not count as a holder record. The catalogue covers only part of the chemical-drug market; source categories do not establish complete market coverage or qualifications.
API registrations
3 loaded active API registrations whose first registered company matches this source company name. Source data as of 2026/11/13 06:41.
| Name | Company / applicant | Registration number | Status | Source update date | View source |
|---|---|---|---|---|---|
| 普罗布考 · No verified English name | Hebei Wan Sui Pharma Co., Ltd. romanized | Y20260000512 | I | 2026/06/23 | CDE ↗ |
| 枸橼酸托法替布 · No verified English name | Hebei Wan Sui Pharma Co., Ltd. romanized | Y20220000399 | A | 2025/12/19 | CDE ↗ |
| 来氟米特 · No verified English name | Hebei Wan Sui Pharma Co., Ltd. romanized | Y20190007063 | A | 2023/03/24 | CDE ↗ |
Only loaded active API registrations not listed as cancelled are shown. A/I are source registration statuses. Records are listed by registration number and do not establish capacity or supply. The register does not identify the associated formulation.
Co-applicant records
1 acceptance records name this company after the first applicant. They are listed separately and are not included in first-applicant drug or filing counts. Source data as of 2026/11/13 06:42.
| Drug | Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|---|
| 狗皮膏 · No verified English name | CYZB2301020 | Supplement | 2023/05/27 | Tianjin Da Ren Tang Jing Wan Hong Pharma Co., Ltd. romanized; Hebei Wan Sui Pharma Co., Ltd. romanized | CDE ↗ |
How current is each source?
- CDE acceptances and review
- Last successful update: 2026/11/13 06:42
- Chemical-drug catalogue
- Last successful update: 2026/11/13 06:39
- Full API register
- Last successful update: 2026/11/13 06:41
- NMPA drug delivery notices
- Last successful update: 2026/11/12 18:32 · Current coverage may be incomplete
First index-page publication dates: 2026-10-29 to 2026-11-13; 2 pages pending. Covers loaded notices only, not a complete historical approval database.
Listed by the company name as recorded in the source, without merging affiliated entities.
This page summarizes loaded records only, without new source queries or collection. Parent companies, subsidiaries, former names and aliases are not merged. Counts from different sources must not be added together. No loaded record does not establish the absence of a filing or registration. Check original records where coverage is incomplete, an update has failed, or a source lies outside the loaded scope.
Fact dates are approval dates, acceptance dates, trial first-publication dates or complete-snapshot observation dates, as applicable. Publication and site-observation dates are separate. Historical backfills are not current-period new events. Exit records cover currently inactive applications with an identifiable complete snapshot, not a full review history.
Drugs with a verified official English name use that name only. Other drug names retain the Chinese source name marked No verified English name; names with a Chinese public page link to that page. Company labels use verified official names, Latin source names, then fixed-rule transliterations marked romanized; Chinese company names are not displayed. Marked unverified drug names and original statutory reference numbers may appear in Chinese.
Legal reference identifiers are retained verbatim. Company labels use official English entries where available, or a visibly marked fixed romanization. Unverified drug names retain the Chinese source name with a No verified English name marker. Other Chinese free text is not displayed; use the source links or source-name columns in CSV exports.